Rossari Biotech Limited — Investor Meet, 23-01-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Rossari Biotech's Q3 FY26 consolidated revenue rose 13% YoY to Rs. 581.7 Cr, with EBITDA at Rs. 68.9 Cr (11.8% margin). All segments grew, led by Animal Health (39%) and Textiles (18%). Exports surged 26% in 9M FY26, offsetting softer domestic demand. The Board approved an in-principle plan for a greenfield specialty chemicals facility in Saudi Arabia, aimed at enhancing global supply chains and leveraging cheaper raw materials. New capacity at Unitop is ramping up, targeting optimal utilization by 2027. Management expects margin improvement from scale, product mix, and new high-margin offerings like approved bio-surfactants, while re-evaluating the B2C segment.